Explore treatments in trials

Bexarotene is used to treat skin cancer, but was also tested as a treatment for MS in a Phase 2 clinical trial.
The results of this trial showed that bexarotene was able to repair myelin in humans. However, participants in the trial experienced some serious side effects so bexarotene will not be taken forward into a Phase 3 study.

Metformin is used to treat type 2 diabetes. However, it is now being tested in combination with clemastine (a hay fever drug) as a treatment for MS.

Vatelizumab is being developed as a treatment for relapsing MS, but the phase 2 trial was terminated early in 2016.

Ublituximab is an antibody, just like those found in the immune system (where antibodies help fight infection)

Tcelna (previously known as Tovaxin) is a treatment being developed for secondary progressive and relapsing MS.

Siponimod (also known as BAF312) is a tablet being developed for secondary progressive MS by Novartis Pharmaceuticals.

Simvastatin is used to treat high cholesterol, but has also shown promise in MS. It’s being tested in a phase 3 clinical trial.

Rituximab (also known as Rituxan or Mabthera) is already licensed to treat some lymphomas, and is being tested as a treatment for MS.

Riluzole is already used to treat motor neurone disease (MND). It's being tested as a treatment for secondary progressive MS in a mid-stage clinical trial.

Latest research and info on the antiviral treatment raltegravir. Learn more about side effects, how it works and see the latest trial results.

Ponesimod is being developed for relapsing MS by Actelion. Read more about side effects and the latest phase 3 clinical trial.

Phenytoin is already used to treat epilepsy. In a phase 2 clinical trial, phenytoin reduced damage to the back of the eye (retina) by 30% compared with placebo. This suggests it could help to protect nerves from damage.

Ozanimod (RPC-1063) is a tablet being developed for relapsing MS. It is currently in phase 3 clinical trials and is produced by Celgene.

Ofatumumab is being developed by Novartis to treat relapsing MS. Read more about side effects and latest clinical trial results.

Ocrelizumab was developed for primary progressive and relapsing MS. Read about how it works and the latest clinical trial results.

Latest research on natalizumab. Learn more about side effects, how it works and when it's likely to be available.

MIS416 is a therapy currently in phase 2 trials for secondary progressive MS. It is being developed by Innate Immunotherapeutics.

Latest research on the antibiotic therapy minocycline. Learn more about side effects, how it works and when it's likely to be available.

MD1003 (high-dose biotin) is a tablet being developed for progressive MS. The treatment is being tested in a second phase 3 trial.

Masitinib (also known as AB1010) is an oral treatment being developed for progressive MS. Find out about the latest trial results.